Baseline characteristics
Myasthenia Gravis, Myasthenia
MYASTHENIA GRAVIS, MYASTHENIA GRAVIS, MYASTHENIA
Of 31 patients screened, 17 met the eligibility criteria and were randomized to receive double‐blind study treatment, and 12 patients completed all three study periods (Fig. CONSORT diagram. DB, double‐blind; ITT, intention‐to‐treat; OLE, open‐label extension; q2w, once every 2 weeks; qw, once weekly. Baseline characteristics (ITT population).ISA, immunosuppressant agent; ITT, intention‐to‐treat; MG, myasthenia gravis; MG‐ADL, Myasthenia Gravis‐Activities of Daily Living; MG‐QOL15r, revised 15‐item Myasthenia Gravis Quality of Life; MGC, Myasthenia Gravis Composite; QMG, Quantitative Myasthenia Gravis; qw, once weekly; q2w, once every 2 weeks.All patients completing the double‐blind phase were eligible to enter the OLE.Includes azathioprine, mycophenolate mofetil, mycophenolic acid, mycophenolate sodium.